In the age subgroup 18–64 years (N = 25,252), there were 634 (2.5%) safety reports of eye disorders with ICIs, mainly anti-PD-1/PD-L1 agents (n = 411, 64.8%, Table 2). The gene discussed is CD274; the disease is eye disorder.